cash flow reconciliationreview2018-10-31
Operating, investing and financing flows differ from the reported change in cash by 2728726, beyond tolerance 1000000.
Revenue
$9.00M
Fiscal year ended 2025-10-31Operating income
-$637.66K
Fiscal year ended 2025-10-31Free cash flow
-$221.53K
Fiscal year ended 2025-10-31Pharma-Bio Serv, Inc. (PBSV) reported revenue of $9.00M and net income of -$100.46K for the fiscal year ended 2025-10-31. This page shows 9 annual periods of income statement, balance sheet and cash flow figures normalized from Pharma-Bio Serv, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Management Consulting Services.
Income
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.00M | $9.51M | $16.98M | $19.40M | $20.12M | $21.56M | $19.51M | $17.80M | $13.30M |
| Cost of revenue | $6.09M | $6.99M | $11.91M | $14.52M | $14.76M | $14.90M | $13.33M | $12.11M | $9.46M |
| Gross profit | $2.91M | $2.52M | $5.07M | $4.88M | $5.36M | $6.67M | $6.18M | $5.69M | $3.84M |
| Operating income | -$637.66K | -$1.29M | $1.12M | $1.17M | -$3.85M | $2.23M | $1.70M | -$1.26M | -$777.82K |
| Net income | -$100.46K | -$777.62K | $1.31M | $1.01M | -$2.09M | $2.05M | $2.09M | $1.28M | -$1.41M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 22.96M | shares 22.97M | shares 23.00M | shares 23.03M | shares 23.16M | shares 23.04M | shares 23.11M | shares 23.10M | shares 23.10M |
| Pretax income | -$94.26K | -$755.45K | $1.69M | $1.19M | -$1.88M | $2.29M | $2.22M | $1.52M | -$773.95K |
| Income tax expense | $6.20K | $22.17K | $377.31K | $181.68K | $213.25K | $239.09K | $135.99K | $2.79M | $3.87K |
| Diluted EPS | $-0.00 | $-0.03 | $0.06 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $-0.06 |
| Selling, general & administrative | $3.55M | $3.80M | $3.95M | $3.71M | $9.21M | $4.44M | $4.48M | $4.60M | $4.66M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | Unavailable | Unavailable | Unavailable | $14.46M | $17.47M | $17.14M | $15.49M | $16.03M | $11.59M |
| Total assets | $13.65M | $16.29M | $19.90M | $20.65M | $23.92M | $29.92M | $26.63M | $25.38M | $22.35M |
| Current assets | $13.39M | $15.70M | $19.40M | $19.94M | $22.82M | $28.58M | $25.97M | $23.41M | $21.68M |
| Total liabilities | $1.74M | $2.58M | $3.78M | $4.09M | $5.01M | $7.20M | $6.03M | $5.11M | $1.60M |
| Current liabilities | $1.74M | $1.89M | $2.15M | $2.11M | $2.67M | $3.79M | $3.67M | $2.57M | $1.54M |
| Total equity incl. NCI | $11.91M | $13.72M | $16.13M | $16.56M | $18.91M | $22.72M | $20.61M | $20.26M | $20.75M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $2.36M | $2.51M | $3.94M | $4.98M | $4.61M | $9.73M | $8.78M | $5.19M | $6.32M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | Unavailable | Unavailable | Unavailable | $1.63M | $2.07M | Unavailable | Unavailable | Unavailable | Unavailable |
Cash flow
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$214.89K | -$566.70K | $1.89M | $592.46K | $804.84K | $1.51M | -$2.21M | $3.72M | -$922.67K |
| Capital expenditures | $6.64K | $159.74K | $7.25K | $19.27K | $10.84K | $55.66K | $57.38K | $122.01K | $56.97K |
| Investing cash flow | -$1.47M | -$1.36M | -$4.22M | -$19.27K | $1.30M | -$28.96K | $1.84M | -$116.01K | -$9.22K |
| Financing cash flow | -$1.75M | -$1.73M | -$1.76M | -$3.53M | -$1.75M | $204.71K | -$155.58K | -$1.80M | -$71.10K |
| Net change in cash | -$3.39M | -$3.68M | -$4.02M | -$3.01M | $330.42K | $1.65M | -$539.75K | $4.44M | -$2.18M |
| Stock-based compensation | $35.08K | $47.55K | $45.08K | $71.64K | $56.24K | $42.88K | $34.12K | $51.64K | $63.88K |
| Common dividends paid | $1.72M | $1.72M | $1.72M | $3.45M | $1.73M | $1.73M | $0 | Unavailable | Unavailable |
| Common share repurchases | $31.44K | $11.26K | $34.34K | $81.99K | $25.97K | $1.70K | $87.89K | $56.52K | $15.43K |
| Depreciation & amortization | $59.87K | $23.31K | $48.09K | $51.11K | $72.73K | $86.28K | $99.10K | $74.60K | $107.68K |
Derived
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 |
|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$221.53K | -$726.44K | $1.88M | $573.19K | $794.00K | $1.46M | -$2.27M | $3.60M | -$979.64K |
| Gross margin | 32.3% | 26.5% | 29.8% | 25.2% | 26.6% | 30.9% | 31.7% | 32.0% | 28.9% |
| Operating margin | -7.1% | -13.5% | 6.6% | 6.1% | -19.2% | 10.3% | 8.7% | -7.1% | -5.8% |
| FCF margin | -2.5% | -7.6% | 11.1% | 3.0% | 3.9% | 6.8% | -11.6% | 20.2% | -7.4% |
| SBC / revenue | 0.4% | 0.5% | 0.3% | 0.4% | 0.3% | 0.2% | 0.2% | 0.3% | 0.5% |
| Current ratio | 7.70x | 8.32x | 9.01x | 9.46x | 8.55x | 7.54x | 7.08x | 9.13x | 14.05x |
| Revenue YoY growth | -5.3% | -44.0% | -12.5% | -3.6% | -6.7% | 10.5% | 9.6% | 33.8% | Unavailable |
| Net margin | -1.1% | -8.2% | 7.7% | 5.2% | -10.4% | 9.5% | 10.7% | 7.2% | -10.6% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 0.1% | 1.7% | 0.0% | 0.1% | 0.1% | 0.3% | 0.3% | 0.7% | 0.4% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | 22.4% | 15.3% | Unavailable | 10.4% | 6.1% | 182.8% | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PBSV in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-09-14View SEC filing
10-Q · Filed 2026-06-15View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-K · Filed 2026-01-29View SEC filing
10-Q · Filed 2025-09-15View SEC filing
10-Q · Filed 2025-06-16View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
cash flow reconciliationreview2017-10-31
Operating, investing and financing flows differ from the reported change in cash by 1180439, beyond tolerance 1000000.